Opinion

Video

Cytopenias Following Imetelstat Treatment in Lower-Risk MDS

Author(s):

Andrew Brunner, MD,Amy DeZern, MD, MHS

An MDS specialist discusses cytopenias associated with imetelstat treatment in patients with lower-risk MDS, highlighting findings from the IMerge clinical trial.

Related Videos
Minoo Battiwalla, MD, MS
Leo I. Gordon, MD
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Related Content
November Recap
December 2nd 2024

Revisit Every OncLive On Air Episode From November 2024

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

Leo I. Gordon, MD
December 2nd 2024

Vice Chair of the B-Cell Lymphomas NCCN Guidelines Maps Critical Changes From 2024

D. Ross Camidge, MD, PhD; Chaplain Rhonda Cooper, primary chaplain, Johns Hopkins Sidney Kimmel Cancer Center
June 13th 2024

Camidge and Cooper on Finding Purpose and Embracing Nuance in Hospital Chaplaincy

OncLive's Top Stories of the Week
November 30th 2024

The OncFive: Top Oncology Articles for the Week of 11/24

Lori Muffly, MD
November 29th 2024

Obe-Cel Approval Expands CAR T-Cell Therapy Options in Relapsed/Refractory ALL